alexa A Novel Strategy For Developing Long Acting Recombinant Proteins: From Bench To Bedside | 60066
ISSN: 2155-952X

Journal of Biotechnology & Biomaterials
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Share This Page

A novel strategy for developing long acting recombinant proteins: From bench to bedside

13th Biotechnology Congress

Fuad Fares

University of Haifa, Israel

Keynote: J Biotechnol Biomater

DOI: 10.4172/2155-952X.C1.066

Abstract
One major issue regarding the clinical use of many peptides is their short half-life due to the rapid clearance from the circulation. To overcome this problem, we succeeded to ligate the signal sequence of O-linked oligosaccharides to the coding sequence of the hormones. The cassette gene that has been used contains the sequence of the carboxyl-terminal peptide (CTP) of human chorionic gonadotropin β (hCGβ) subunit. The CTP contains 28 amino acids with four O-linked oligosaccharide recognition sites. It was postulated that O-linked oligosaccharides add flexibility, hydrophilicity and stability to the protein. On the other hand, it was suggested that the four O-linked oligosaccharides play an important role in preventing plasma clearance and thus increasing the half-life of the protein in circulation. Using this strategy, we succeeded to ligate the CTP to the coding sequence of follitropin (FSH), thyrotropin (TSH), erythropoietin (EPO) growth hormone (GH) and thus to increase the longevity and bioactivity of these proteins in vivo. Interestingly, the new analogs of FSH and GH were found nonimmunogenic in human and it is already passed successfully clinical trials phase III and phase II respectively. Moreover, FSH long acting was approved by the European Commission (EC) for treatment of fertility. In addition, our results indicated that long acting GH is not toxic in monkeys and the results from clinical trials phase I and phase II seem to be promising. Designing long acting peptides will diminish the cost of these drugs and perhaps reduce the number of injections in the clinical protocols.
Biography

Fuad Fares has completed his MSc and DSc studies at the Faculty of Medicine, Technion-Israel Institute of Technology and Postdoctoral studies at the Department of Molecular Biology and Pharmacology, School of Medicine, Washington University, St. Louis Missouri, USA. He has developed the Molecular Genetic Laboratory at Carmel Medical Center, Haifa, Israel and led the laboratory for last 20 years until 2015. He is the Head of Molecular Genetic Laboratory at the Department of Human Biology, University of Haifa, Israel since 2004 and teaching genetics, genetic engineering and endocrinology at the Faculty of Natural Sciences at University of Haifa, Israel. He has published more than 90 manuscripts in reputed journals and serving as a Member of the Israel Council for Higher Education since 15 years. Moreover, he is the Founder and the Inventor of PROLOR Biotech Company for designing long-acting recombinant proteins.

Email: [email protected] [email protected]

Top